Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Assistance Publique - Hôpitaux de Paris |
---|---|
Information provided by: | Assistance Publique - Hôpitaux de Paris |
ClinicalTrials.gov Identifier: | NCT00339196 |
MULTICENTERS. Uncontrolled and open phase II study. Evaluation of the effectiveness of a treatment associating 5 Azacytidine,Valproic acid ,Retinoic Acid at subjects-reached of syndromes myelodysplasia and acute myeloïd leukaemia Hematological response at 6 months Uncontrolled prospective cohort.
Condition | Intervention | Phase |
---|---|---|
Acute Myelogenous Leukaemia (AML) Myelodysplastic Syndrome (MDS) |
Drug: 5 azacytidine - Valproïc acid- Retinoic acid |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Multi Centers, Open-Trial Phase II Study Evaluating 5-Azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®) in Patients With Acute Myelogenous Leukemia and High Risk Myelodysplasia. |
Estimated Enrollment: | 25 |
Study Start Date: | July 2006 |
Estimated Study Completion Date: | July 2008 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
de novo AML without previous treatment in elderly patients (FAB-M3 excluded) , if :
Exclusion Criteria:
Contact: Emmanuel RAFFOUX, MD | +33 (0) 1 42 49 96 49 | emmanuel.raffoux@sls.aphp.fr |
France | |
Chu Saint Louis | Recruiting |
PARIS, France, 75010 | |
Contact: Emmanuel RAFFOUX, MD + 33 (0) 1 42 49 96 49 emmanuel.raffoux@sls.aphp.fr | |
Principal Investigator: Emmanuel RAFFOUX, MD |
Principal Investigator: | Emmanuel RAFFOUX, MD, | Assistance Publique - Hôpitaux de Paris |
Study ID Numbers: | P050202 |
Study First Received: | June 12, 2006 |
Last Updated: | March 14, 2007 |
ClinicalTrials.gov Identifier: | NCT00339196 History of Changes |
Health Authority: | France: Ministry of Health |
AML MDS High risk Demethylating agents HDAC Inhibitors |
Antimetabolites Neurotransmitter Agents Tranquilizing Agents Precancerous Conditions Hematologic Diseases Myelodysplastic Syndromes Psychotropic Drugs Central Nervous System Depressants Leukemia, Myeloid Antimanic Agents Leukemia, Myeloid, Acute |
Valproic Acid Keratolytic Agents Leukemia Preleukemia Acute Myelocytic Leukemia Acute Myeloid Leukemia, Adult Azacitidine Tretinoin Bone Marrow Diseases Anticonvulsants |
Antimetabolites Neurotransmitter Agents Antimetabolites, Antineoplastic Precancerous Conditions Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Physiological Effects of Drugs Psychotropic Drugs Leukemia, Myeloid, Acute Valproic Acid Keratolytic Agents Leukemia Preleukemia Therapeutic Uses Azacitidine |
Dermatologic Agents Neoplasms by Histologic Type Tranquilizing Agents Hematologic Diseases Myelodysplastic Syndromes Central Nervous System Depressants Enzyme Inhibitors Leukemia, Myeloid Antimanic Agents Pharmacologic Actions Neoplasms GABA Agents Tretinoin Bone Marrow Diseases Central Nervous System Agents |